Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 6;10:2040622319847881. doi: 10.1177/2040622319847881

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2019

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Outcomes of interferon α2a treatment.

Comparisons of (a) uveitis relapse rates (p = 0.000002, p = 0.000004, p = 0.000002), (b) the minimum concomitant corticosteroid dose (p = 0.000882, p = 0.001112, p = 0.000376), and (c) the number of immunosuppressive agents (p = 0.00054, p = 0.000949, p = 0.00004) at 6 months, 12 months, and last follow up with that at baseline (pretreatment Behçet’s uveitis patients), shown as median and range. The significance was determined using two-tailed Wilcoxon test. **p-value < 0.01, ***p-value < 0.001, IS, immunosuppressant.